Replies to post #44631 on RespireRx Pharmaceuticals Inc (RSPI)

[oldstocks]

Eli Lilly was investigating Talampanel prior to 2010
Ticker: LLY $752

For the treatment of epilepsy, malignant gliomas and ALS
Development codes LY-300164 , LY300164

Results from the trial for ALS have been found negative.
Talampanel is not currently under development.
It showed effectiveness for epilepsy in clinical trials but its development was suspended due to its poor pharmacokinetic profile, namely a short terminal half-life (3 hours) that necessitated multiple doses per day.

RespireRx Pharmaceuticals KRM–II–81 has shown promising results for Epilepsy.
Has fully suppressed the epileptiform activity in the excised brain tissue from a 19-year-old patient with pharmaco-resistant epilepsy.

KRM–II–81 is the Golden Ticket for RSPI